Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2025-12-25 @ 7:46 PM
Study NCT ID:
NCT03764735
Status:
COMPLETED
Last Update Posted:
2022-01-19
First Post:
2018-11-30
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of SkQ1 as Treatment for Dry-eye Syndrome
Sponsor:
Mitotech, SA
Organization:
Study Overview
Official Title:
A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VISTA-1
Brief Summary:
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Detailed Description:
Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over the course of approximately 9 weeks. Qualified subjects are randomized 1:1:1 to receive either High Dose SkQ1 ophthalmic solution, Low Dose SkQ1 ophthalmic solution, or Placebo (vehicle of SkQ1 ophthalmic solution).
The Primary Endpoints are:
Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;
Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom
The Primary Endpoints are:
Change from Baseline (Visit 2) to Visit 5 in Corneal Fluorescein Staining;
Change from Baseline (Visit 2) to Visit 5 in Grittiness Symptom
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: